Chemotherapy for Uterus Cancer
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
Breast Cancer Update .com - Web Guide 1 2003
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer | Breast Cancer ...
Chemotherapy protocol definition form | Download Scientific Diagram
Chemotherapy-Induced Nausea and Vomiting: From Guideline to Clinical Practice - Pharmacy Connection
Dexamethasone-Sparing Strategies Using Netupitant and Palonosetron Fixed-Dose Combination for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: A Case Series
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
Pregnancy-Associated Breast Cancer
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content | JCO Clinical Cancer Informatics
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) - Annals of Oncology
Protocol MCP841 chemotherapy regimen. | Download Table
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
JCM | Free Full-Text | Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
AC Chemotherapy Regimen (Doxorubicin + Cyclophosphamide) - PDF Free Download
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Chemotherapy Administration Sequencing: An Update on the Current Literature
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study - ScienceDirect
